9 completed, 2 recruiting, 1 withdrawn. 12 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 9, Recruiting 2, Withdrawn 1 |
Follow Enterocolitis, Pseudomembranous: new trials by email Literature Review of Enterocolitis, Pseudomembranous trials Research Report on Enterocolitis, Pseudomembranous
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT) Alanyl-glutamine - Clostridioides Difficile Infection, Clostridium Difficile Infection | Phase 2 | Recruiting | University of Virginia | 260 | 2021-06-01 | 2024-10-26 |
| Multicentre Blinded Comparison of Lyophilized Sterile Fecal Filtrate to Lyophilized Fecal Microbiota Transplant in Recurrent Clostridioides Difficile Infection Lyophilized fecal microbiota transplant, Lyophilized sterile fecal filtrate - Clostridia Difficile Colitis, Clostridium Difficile Diarrhea | Phase 2 | Completed | University of Alberta | 138 | 2019-03-21 | 2024-06-04 |
| Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile Infection Vancomycin, Placebo - Recurrent Clostridium Difficile Infection, Clostridium Difficile Infection | Phase 2 | Completed | University of Wisconsin, Madison | 79 | 2018-05-21 | 2025-05-25 |
| Stool Transplants to Treat Refractory Clostridium Difficile Colitis fecal microbiota - Clostridium Difficile Colitis | Phase 2 | Recruiting | Duke University | 77 | 2016-04-01 | 2026-08-27 |
| Fecal Microbiota Transplantation for Severe Clostridium Difficile Infection Single-infusion FMT, Vancomycin (before randomization), multiple-infusion FMT - Clostridium Difficile, Pseudomembranous Colitis | Phase 2 | Completed | Catholic University of the Sacred Heart | 58 | 2016-03-01 | 2018-02-09 |
| Transplantation of Cultured Gut Microflora to Repeat Antibiotic-induced Diarrhea Due to Clostridium Difficile Cultured human intestinal microbiota, Vancomycin, Metronidazole - Clostridium Difficile | Phase 2 | Completed | Per Hellström | 60 | 2014-10-01 | 2019-01-09 |
| Stool Transplant in Pediatric Patients With Recurring C. Difficile Infection FMT, placebo - Clostridium Difficile Colitis | Phase 2 | Completed | MemorialCare Health System | 9 | 2013-10-01 | 2016-09-01 |
| Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections LFF571, Vancomycin (POC) - Moderate Clostridium Difficile Infection | Phase 2 | Completed | Novartis Pharmaceuticals | 109 | 2010-10-01 | 2020-12-19 |
| Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults Clostridium difficile toxoids A and B (Low-dose with adjuvant), Clostridium difficile toxoids A and B (Low-dose without adjuvant), Clostridium difficile toxoids A and B (high-dose with adjuvant) - Clostridium Difficile Infection, Diarrhea | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 650 | 2010-10-01 | 2018-07-18 |
| Safety and Clinical Effectiveness of Oral Probiotic MIYA-BM to Prevent Recurrent Clostridium Difficile Infections MIYA-BM Fine Granules (CBM588), Placebo Fine Granules (without CBM588) - Clostridium Difficile Infection | Phase 2 | Withdrawn | Osel, Inc. | 2010-02-01 | 2013-11-11 | |
| A Study of the Absorption of GT267-004 in Patients With Clostridium Difficile-Associated Diarrhea tolevamer potassium-sodium (GT267-004) - Pseudomembranous Colitis, Clostridium Difficile Diarrhea | Phase 2 | Completed | Genzyme, a Sanofi Company | 24 | 2006-09-01 | 2015-03-19 |
| A Study of GT160-246 Versus Vancomycin in Patients With Clostridium Difficile-Associated Diarrhea GT160-246 - Clostridium Difficile-Associated Diarrhea, Clostridium Enterocolitis | Phase 2 | Completed | Genzyme, a Sanofi Company | 300 | 2002-02-01 | 2015-03-05 |
Clostridium Infections (5) · Diarrhea (2) · Dysentery (2) · Bacterial Infections (1) · Colitis (1) · Colonic Diseases (1) · Digestive System Diseases (1) · Enterocolitis (1) · Gastroenteritis (1) · Gastrointestinal Diseases (1) · Gram-Positive Bacterial Infections (1) · Intestinal Diseases (1)
Bacterial Infections and Mycoses (12) · Infections (12) · Bacterial Infections (11) · Digestive System Diseases (11) · Enterocolitis (11) · Gastroenteritis (11) · Gastrointestinal Diseases (11) · Gram-Positive Bacterial Infections (11) · Intestinal Diseases (11) · Clostridium Infections (7) · Pathological Conditions, Signs and Symptoms (2) · Signs and Symptoms (2) · Signs and Symptoms, Digestive (2)
Vancomycin (4) · Fecal Microbiota Transplantation (2) · Adjuvants, Pharmaceutic (1) · Fluoridation (1) · Glutamine (1) · LFF571 (1) · Metronidazole (1) · Saline Solution (1) · Sodium Chloride (1) · alanylglutamine (1) · styrenesulfonic acid polymer (1)
Genzyme, a Sanofi Company (2) · Catholic University of the Sacred Heart (1) · Duke University (1) · MemorialCare Health System (1) · Novartis Pharmaceuticals (1) · Osel, Inc. (1) · Per Hellström (1) · Sanofi Pasteur, a Sanofi Company (1) · University of Alberta (1) · University of Virginia (1) · University of Wisconsin, Madison (1)
United States (7) · Canada (4) · Puerto Rico (1) · Sweden (1) · United Kingdom (1)
Dina Kao, MD (1) · Gary M Cox, MD (1) · Lynne V. McFarland, Ph.D. (1) · Nasia Safdar, MD PhD (1) · Sonia Michail, MD (1)
PMID 10440607, PMID 11171619, PMID 21871249, PMID 23323867, PMID 25534724, PMID 25534727, PMID 27013431, PMID 29851107, PMID 31537446, PMID 37474181, PMID 40601321, PMID 40997843, PMID 9712236